A pioneering medical trial has found that administering stem cells to unborn babies suffering from spina bifida while undergoing fetal surgery could constitute a "major milestone" in treating birth defects.
Study Parameters and Security
The research conducted in the United States focused on six unborn babies with the 'open' form of spina bifida. Doctors administered placenta-derived mesenchymal stem cells to the surface of the baby's spinal cord while the defect was being closed.
Critically, the cell therapy was found to be safe. The study team reported that the therapy did not induce neoplasms, disrupt the healing process, or prevent the reversal of associated brain abnormalities.
Positive Developments
Post-birth MRI scans showed a full resolution of brainstem displacement in each of the babies. This brain structure normalization is strongly associated with enhanced physical outcomes.
"Should it enable a greater number of infants able to walk who wouldn't have, then it would become the new treatment paradigm," said the lead researcher. "The outcomes appear extremely promising and pave the way for a variety of prospective novel therapies."
Broader Impact and Encouragement
Experts not involved in the trial proposed that further confirmation of these apparent benefits could herald a "new era" in in-utero treatment. The potential to improve neurological damage occurring during fetal development is viewed as a revolutionary objective.
Particularly welcome would be better management of continence and digestive health, which are typical difficulties for those diagnosed with this condition.
Looking Ahead
While this initial trial involved a limited number of patients, its confirmed tolerability and hopeful trends provide a strong foundation for expanded clinical research. The combination of regenerative medicine with established fetal surgery techniques holds considerable promise for improving the prognosis for infants diagnosed prenatally with myelomeningocele.